Please login to the form below

Not currently logged in
Email:
Password:

certolizumab pegol

This page shows the latest certolizumab pegol news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

Latest news

  • NICE approves UCB Pharma’s Cimzia NICE approves UCB Pharma’s Cimzia

    The draft guidance states that Cimzia (certolizumab pegol) can be used on its own or in combination with methotrexate when other drugs have not worked or are not suitable to treat ... We hope that adding certolizumab pegol to this list will mean that

  • NICE set to recommend seven biologics for severe rheumatoid arthritis NICE set to recommend seven biologics for severe rheumatoid arthritis

    NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome

  • NICE backs biosimilars in rheumatoid arthritis guidance NICE backs biosimilars in rheumatoid arthritis guidance

    The recommended brands are: AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB's Cimzia (certolizumab pegol), MSD/Johnson &Johnson's Simponi (golimumab), Roche's RoActemra (tocilizumab), Bristol-Myers Squibb's

  • UCB moves Cimzia into phase III trials for psoriasis UCB moves Cimzia into phase III trials for psoriasis

    Cimzia (certolizumab pegol) received FDA approval for its use in patients with psoriatic arthritis in late 2013, in addition to existing licences for rheumatoid arthritis and Crohn's disease, but it

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...